Company evaluating systemic recombinant human DNase I (DNase I) in combination with chemotherapy and immunotherapy platforms for the treatment of pancreatic carcinoma, colorectal cancer and other ...
Data presented at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting Findings demonstrate that by degrading neutrophil extracellular traps (NETs), DNase I not ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results